This website contains information based on the Summary of Product Characteristics (SPC), as approved by the European Commission on Jivi (damoctog alfa pegol), Kovaltry (octocog alfa) and Kogenate FS (octocog alfa). It is intended to provide information to an international audience. In countries outside the EU, the local Product Information applies.
Saxena K, Lalezari S, Oldenburg J, et al. Efficacy and safety of BAY 81-8973, a full-length recombinant factor VIII: results from the LEOPOLD I trial. Haemophilia. 2016;22(5): 706-712.Return to content
Kavakli K, Yang R, Rusen L, et al. Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). J Thromb Haemost. 2015;13(3):360-36.Return to content
Ljung R, Kenet G, Mancuso M, et al. BAY 81-8973 safety and efficacy for prophylaxis and treatment of bleeds in previously treated children with severe haemophilia A: results of the LEOPOLD Kids Trial Haemophilia. 2016;22(3):354-60.Return to content